Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma
A Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of YH004 In Subjects With Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma
Sponsor: Eucure (Beijing) Biopharma Co., Ltd
A PHASE1 clinical study on Advanced Solid Tumors and Relapsed Or Refractory Non-Hodgkin Lymphoma, this trial is ongoing. The trial is conducted by Eucure (Beijing) Biopharma Co., Ltd and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eucure (Beijing) Biopharma Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .